пятница, 20 января 2017 г.

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead


The company did not say whether the data was disappointing or merely insufficient to seek accelerated approval. Cowen and Co analyst Steve Scala downgraded his rating on Bristol shares to "market perform" from "outperform" and lowered his price target on the stock to $65 from $85.



from Biotech News